Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

STRIVES: Status-Neutral TeleHealth Concierge Intervention for Unhoused People Who Use Drugs Via Engagement Through Street Medicine

NCT07931612 is registered in ClinicalTrials.gov with University of Miami as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07931612 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
STRIVES: Status-Neutral TeleHealth Concierge Intervention for Unhoused People Who Use Drugs Via Engagement Through Street Medicine
Lead sponsor
University of Miami
Phase
Not applicable
Overall status
Not yet recruiting
Start date
May 1, 2027
Completion date
July 1, 2030
Enrollment
200 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c (hcv), hiv, homelessness, substance use disorder (sud)

Arms

As registered; 2 arms.

  • Standard of Care Group (Off-site clinic referral and patient navigation) Active comparatorStandard of Care (Patient Navigation to Off-Site Clinic)

    Participants in this arm receive standard patient navigation and referral services for healthcare and social support needs for one year.

  • Status-Neutral Telehealth Concierge (SN-THR) Group ExperimentalStatus-Neutral Telehealth Concierge (SN-THR)

    Participants in this arm receive the SN-THR intervention, a multidisciplinary street medicine and telehealth program providing integrated medical care, behavioral health services, care coordination, and social support for one year.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Antiretroviral Adherence for Treatment/Prevention Baseline, 3, 6, 9, and 12 months

    Proportion of participants adherent to Antiretroviral Therapy (ART) for HIV treatment/prevention. HIV treatment adherence (ART adherence) will be defined by HIV RNA level \<200 copies/mL for PWH. PrEP adherence will be defined by any of the following: Dried Blood Spot (DBS) tenofovir diphosphate (TFV-DP) level of 700 fmol/punch for tenofovir disoproxil fumarate (TDF); DBS TFV-DP level of 950 fmol/punch for tenofovir alafenamide (TAF); or documentation of long-acting ART/PrEP (cabotegravir injection in the previous 8 weeks or lenacapavir injection in the previous 6 months) via EHR abstraction.

Lead sponsor's other trials

University of Miami, most recent start first.

Similar trials

Same condition (Hepatitis C) and phase, most recent start first.